MSQC7

SILu^™MAB Stable-Isotope Labeled Universal Monoclonal Antibody Standard（SILu MAB安定同位体標識ユニバーサルモノクローナル抗体スタンダード） ヒト

recombinant, expressed in CHO cells

• 別名: SILu^™MAB Stable-Isotope Labeled Universal Monoclonal Antibody Standard human, IgG4 kappa, Isotopically labeled mAb LC/MS Standard, Mass Spectrometry Monoclonal Antibody Standard
• UNSPSCコード: 12352200
• NACRES: NA.12

特性

• リコンビナント: expressed in CHO cells
• 品質水準: 200
• 抗体製品タイプ: primary antibodies
• アッセイ: ≥90% (SDS-PAGE)
• 包装: vial of 100 μg (± 10% Lot-specific vial content given on certificate of analysis)
• 輸送温度: wet ice
• 保管温度: −20°C

詳細

アプリケーション

Multiplex Universal Peptide Quant Approach Using Microflow LC/MS/MS for Non-human Preclinical PK Study of Therapeutic Monoclonal Antibodies ( Webinar )

Applying Best-in-Class HPLC Column Technologies to the Analysis of Proteins and Biotherapeutics Using SILuMab ( Webinar )

特徴および利点

Universal Peptide Sequence Location
YGPPCPPCPAPEFLGGPSVFLFPPKPK Heavy Chain (IgG4 Stabilized)
VVSVLTVLHQDWLNGK Heavy Chain (IgG1, IgG3, IgG4)
GFYPSDIAVEWESNGQPENNYK Heavy Chain (IgG1, IgG4)
TTPPVLDSDGSFFLYSR Heavy Chain (IgG4)
SGTASVVCLLNNFYPR Light Chain (kappa)
VDNALQSGNSQESVTEQDSK Light Chain (kappa)
DSTYSLSSTLTLSK Light Chain (kappa)

Underlined is a Serine-Proline substitution in the hinge region that is present in many human IgG4-based therapeutic monoclonal antibodies

SILuMab has been validated as an internal standard for quantitation of relevant biotherapeutics in a complex biological matrix by MRM-based LC-MS/MS.

• SILuMab yielded reproducible, linear curves from 0.1 μg/mL to 1000 μg/mL without enrichment or depletion.
• Good agreement was observed between multiple peptides derived from the same target.
• Label incorporation was determined to be >98% by mass spectrometry.
• Sequence coverage was confirmed by peptide mapping.

物理的形状

Supplied as a lyophilized powder containing phosphate buffered saline

調製ノート

Produced utilizing enriched media containing stable isotope labeled amino acids are ¹³C6, ¹⁵N4-labeled arginine and ¹³C6, ¹⁵N2-labeled lysine

SILuMab design is optimized to be used as an internal standard for quantitation of monoclonal antibodies as well as Fc-fusion therapeutics. Because of overlap with the common sequences in the Fc region with candidate antibodies, SILuMab provides univer­sal utility, thus eliminating the need for production of candidate-specific internal standards.

再構成

SILuMab recovery is maximized when 0.1% formic acid is used for reconstitution of the lyophilized product. Reconstitution with other solvents may reduce recovery. Do not freeze after reconstitution.
Procedure

• Briefly centrifuge the vial at ~10,000 x g to collect the product at the bottom of the vial.
• Add 500 μL of purified water containing 0.1% formic acid to the vial.
• Mix the contents by gently inverting the vial a minimum of 5 times.
• Allow the vial to stand at room temperature for a minimum of 15 minutes and repeat mixing by inversion.

アナリシスノート

SILuMAb K4 Heavy Chain

EVQLVESGGGLVQPGGSLRLSCVASGFTLNNYDMHWVRQGIGKGLEWVSKIGTAGDRYYAGSVKGRFTISRENAKDSLYLQMNSLRVGDAAVYYCARGAGRWAPLGAFDIWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG

SILuMAb K4 Light Chain

QSALTQPRSVSGSPGQSVTISCTGTSSDIGGYNFVSWYQQHPGKAPKLMIYDATKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGDYTPGVVFGGGTKLTVLTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Target overlap areas are underlined

Package size based on protein content determined by A₂₈₀ using an extinction coefficient (E^0.1%) of 1.4

Quantitative
MRM settings provided (xls)

法的情報

This product is licensed under U.S. Patent No. 7,396,688 and foreign counterparts from E. I. du Pont de Nemours and Company. The purchase of this product conveys to the buyer the nontransferable right to use the purchased amount of the product for research and development only, including services for a third party for consideration. The buyer cannot sell or otherwise transfer this product, its components or materials made using this product or its components to a third party. Information about licenses for excluded uses is available from: E. I. du Pont de Nemours and Company; Attn: Associate Director, Commercial Development; DuPont Experimental Station E268; 200 Powdermill Rd.; Wilmington, DE 19803; 1-877-881-9787 (voice), 1-302-695-1437 (fax), licensing@dupont.

SILu is a trademark of Sigma-Aldrich Co. LLC

安全性情報

• 保管分類コード: 13 - Non Combustible Solids
• WGK: WGK 1
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable